SNDX

Syndax Pharmaceuticals Inc

SNDX, USA

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.

https://syndax.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
SNDX
stock
SNDX

New Analyst Forecast: $SNDX Given $56 Price Target Quiver Quantitative

Read more →
SNDX
stock
SNDX

Syndax Pharmaceuticals (NASDAQ:SNDX) Given "Buy" Rating at BTIG Research MarketBeat

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$39.3077

Analyst Picks

Strong Buy

9

Buy

2

Hold

1

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

14.64

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-52.60 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-11.00 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-154.05 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

3.78

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 98.34% of the total shares of Syndax Pharmaceuticals Inc

1.

BlackRock Inc

(12.1392%)

since

2025/06/30

2.

Kynam Capital Management, LP

(9.8907%)

since

2025/06/30

3.

Goldman Sachs Group Inc

(6.7298%)

since

2025/06/30

4.

Vanguard Group Inc

(5.8438%)

since

2025/06/30

5.

Eversept Partners, LLC

(4.7194%)

since

2025/06/30

6.

Bank of America Corp

(4.4565%)

since

2025/06/30

7.

State Street Corp

(3.9966%)

since

2025/06/30

8.

Vanguard Total Stock Mkt Idx Inv

(2.9743%)

since

2025/07/31

9.

StemPoint Capital LP

(2.7543%)

since

2025/06/30

10.

Franklin Resources Inc

(2.7393%)

since

2025/06/30

11.

Point72 Asset Management, L.P.

(2.4697%)

since

2025/06/30

12.

Catalio Capital Management, LP

(2.4431%)

since

2025/06/30

13.

Kingdon Capital Management LLC

(2.4378%)

since

2025/06/30

14.

iShares Russell 2000 ETF

(2.3892%)

since

2025/08/31

15.

Geode Capital Management, LLC

(2.379%)

since

2025/06/30

16.

Assenagon Asset Management SA

(2.3682%)

since

2025/06/30

17.

Woodline Partners LP

(2.1972%)

since

2025/06/30

18.

Qube Research & Technologies

(1.9339%)

since

2025/06/30

19.

Millennium Management LLC

(1.8558%)

since

2025/06/30

20.

Sphera Funds Management Ltd.

(1.8244%)

since

2025/06/30

21.

SPDR® S&P Biotech ETF

(1.7827%)

since

2025/08/31

22.

Sofinnova Ventures

(1.7697%)

since

2025/06/30

23.

BNP Paribas Investment Partners SA

(1.678%)

since

2025/06/30

24.

Eventide Healthcare & Life Sciences I

(1.6416%)

since

2025/06/30

25.

Franklin Biotechnology Discv A(acc)USD

(1.1811%)

since

2025/08/31

26.

Vanguard Institutional Extnd Mkt Idx Tr

(1.0864%)

since

2025/07/31

27.

Belfius Equities Cure C Cap

(1.0742%)

since

2025/08/31

28.

Fidelity Small Cap Index

(0.9922%)

since

2025/06/30

29.

BNP Paribas Health Cr Innovtr Cl Cap

(0.9662%)

since

2025/07/31

30.

BlackRock Advantage Small Cap Core Instl

(0.9013%)

since

2025/07/31

31.

Franklin US Small Cap Growth Equity

(0.8813%)

since

2025/06/30

32.

Franklin Small Cap Growth Adv

(0.8097%)

since

2025/07/31

33.

iShares Russell 2000 Growth ETF

(0.8018%)

since

2025/08/31

34.

BNP Paribas US Small Cap ClassicC

(0.7151%)

since

2025/07/31

35.

Rhenman Healthcare Equity L/S RC2 SEK

(0.6663%)

since

2025/05/31

36.

Franklin Biotechnology Discovery A

(0.6402%)

since

2025/07/31

37.

Invesco MSCI World ETF

(0.6203%)

since

2025/07/31

38.

iShares Biotechnology ETF

(0.5731%)

since

2025/08/31

39.

Fidelity Extended Market Index

(0.5382%)

since

2025/07/31

40.

Schwab US Small-Cap ETFâ„¢

(0.4768%)

since

2025/08/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.5536

Latest Release

Date

2025-09-30

EPS Actual

-0.7

EPS Estimate

-0.73

EPS Difference

0.03

Surprise Percent

4.1096%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(2)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.3)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(2.5)
Momentum
No Momentum(3)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(1.5)
Value
Overpriced(2)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.